MAPT and Alzheimer disease: For example, β-amyloid1–42 (Aβ1–42), total tau protein (T-tau), and hyperphosphorylated tau (P-tau), the core biomarkers of AD that are mostly used in clinical practice, are derived from CSF and have shown high sensitivity and specificity in the identification of AD patients.